Kiniksa Pharmaceuticals Reports Strong 2025 ARCALYST Revenue and Positive 2026 Guidance

summarizeSummary

Kiniksa Pharmaceuticals reported strong unaudited 2025 ARCALYST revenue with 62% year-over-year growth and issued positive 2026 revenue guidance. The company also highlighted a robust cash position and pipeline advancements.

check_boxKey Events

• Strong 2025 ARCALYST Revenue

  Unaudited net product revenue for ARCALYST reached $677.5 million for the full year 2025, representing approximately 62% year-over-year growth.

• Positive 2026 Revenue Guidance

  Kiniksa expects ARCALYST net product revenue for 2026 to be between $900 million and $920 million.

• Robust Financial Position

  As of December 31, 2025, the company had $414.1 million in cash, cash equivalents, and short-term investments with no debt, and expects to remain cash flow positive annually.

• Pipeline Advancement

  Phase 2 data for KPL-387 in recurrent pericarditis is expected in the second half of 2026, and a Phase 1 trial for KPL-1161 is planned to initiate by year-end 2026.

auto_awesomeAnalysis

Kiniksa Pharmaceuticals announced robust unaudited full-year 2025 net product revenue for ARCALYST, demonstrating significant year-over-year growth. The company also provided strong revenue guidance for 2026, indicating continued commercial momentum for its key product. Furthermore, Kiniksa reported a healthy cash position with no debt and expects to remain cash flow positive, providing financial stability to advance its pipeline. These updates, combined with progress on its KPL-387 and KPL-1161 programs, suggest a positive outlook for the company's financial performance and future growth catalysts.